View Report Details Global Intravenous (I.V.) Iron Drugs Market Report ----------------------------------------2015
View Report Details Executive Summary Iron deficiency anemia is the most common form of anemia throughout the world. It is estimated that two billion people suffer from iron deficiency anemia worldwide. To address iron deficiency, iron therapy is important being the critical factor in the production of red blood cells. Around 4.5 million Americans are diagnosed and suffering from iron deficiency anemia (IDA). Generally, daily oral iron is the first line therapy for most IDA patient but for many patients oral iron therapy fails as a consequence of compliance, efficacy and side effects like constipation and gastro intestinal disorders. When oral supplements fail to meet the requirement, intravenous (I.V.) iron therapy is used, in which iron is directly injected with a needle into a vein. Iron given intravenously allows larger amounts of iron to be provided to patients while avoiding many of the side effects and treatment compliance issues associated with oral iron, and can result in faster rises in hemoglobin levels. In the US, a small fraction of non-dialysis CKD patients who are diagnosed with IDA are currently being treated with I.V. iron, and thus a significant opportunity is there for the market. The key factors driving growth of the global I.V. iron industry include iron deficiency in hemodialysis patient cases, growing number of ERSD patients, prevalence of iron deficiency in women, increasing global healthcare expenditure, increasing global ageing population and large potential in new therapeutic areas. Some of the noteworthy trends and developments of this industry are penetration of I.V. iron in obstetrics and gynecology area, new product development and increase in awareness of disease. However, the growth of this sector is hindered by potential risks of using I.V. iron, emerging anemia management therapies and strict regulatory structures. The report provides a comprehensive study of iron product market and I.V. iron market globally. It also provides detailed information for key regional markets of I.V iron industry. The competition in the global I.V. iron market is stiff among large players like Galenica Group, AMAG Pharmaceuticals Inc. and Actavis Plc. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth. By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Iron deficiency anemia affects approximately 15% of the world population. Global Market for Iron Products (2010-2014)
The global market for iron products was worth US$... billion in 2014 depicting an increase of …% from US$... billion in 2013. Despite the decline in market after 2011 the market has been steadily growing at a CAGR of …% during the period spanning from 2010 to 2014.
US$ Billion
The global I.V. iron market was worth US$... million in 2014, an increase of …% from market value of US$... million in 2013. Despite the decline in market after 2011 the market has been steadily growing at a CAGR of …% during the period spanning 2009 to 2014.
2010
2011
2012
2013
2014
Global I.V. Iron Drugs Market Value (2009-2014)
Iron products are chiefly divided into two types: oral and intravenous (I.V.). The global iron products market is dominated by oral products due to easy of usage. In 2014, oral iron products held …% share of the total revenue generated by the global iron products industry whilst intravenous products accounted for the remaining …% share.
US$ M illion
Global Iron Products Market Share by Segments (2014)
2009
2010
2011
2012
2013
2014 Intravenous Iron
Oral Iron
70% of the worldwide I.V. iron market is in Nephrology. Global I.V. Iron Drug Market Share by Product (2014)
In 2014, Venofer remained the gold standard product in dialysis patients with …% of the global I.V. iron market share followed by Ferinject with …% of the market share. Feraheme and Gluconate had …% and …% of the total market share respectively in 2014. The US market represents more than …% of the worldwide I.V. iron market. The US I.V. iron market in 2014 the I.V. iron market grew by …% to US$... million.
Venofer Ferinject ISS Feraheme Gluconate Other
US I.V. Iron Drug Market Value (2009-2014)
Venofer, owned by Galenica, leads the US iron market with …% of the market share. Fresenius has a sublicense agreement that allows it to distribute Venofer to the dialysis market in the US and Canada. Galenica also markets Injectafer Brand name of Ferinject in the US with …% of the market share.
US$ M illion
US I.V. Iron Drug Market Share by Product (2014)
2009
2010
2011
2012
2013
2014
Venofer
Feraheme
Gluconate
Injectafer
Other
European market growth is driven by Ferinject, mostly outside dialysis. US Non-dialysis I.V. Iron Drug Market Volume (2010-2014)
Thousand Grams
In the US, … thousand grams of I.V. iron were administered for the treatment of non-dialysis patients with IDA in 2014. Approximately half of the I.V. iron administered in the country was for the treatment of non-dialysis patients with CKD and the other half was for non-CKD patients with IDA due to other causes. In the US non-dialysis I.V. iron market, Venofer has the largest market share of …% followed by INFed with …% share in 2014. Feraheme, Injectafer and Ferrlecit account for …%, …% and …% of the non-dialysis I.V. iron market share respectively.
2010
2011
2012
2013
The European market represents one-third of the worldwide I.V. iron market. The market is continuously growing at a CAGR of …% for the period spanning 2009 to 2014. The market value of I.V. iron in Europe amounted to US$... million in 2014.
2014
US Non-dialysis I.V. Iron Drug Market Share by Product (2014)
US$ M illion
European I.V. Iron Drug Market Value (2009-2014)
Venofer
INFeD
Generic sodium ferric gluconate
Injectafer Ferrlecit
Dexferrum
Feraheme
2009
2010
2011
2012
2013
2014
Vifor Pharma owns about two-third of the worldwide I.V. iron market
US$ M illion
Global I.V. Iron Drug Market Forecast (2014-2019F)
2014
2015F
2016F
2017F
2018F
2019F
•
Intravenous iron therapies find maximum use in nephrology segment, as a high percentage of the patients suffering from chronic kidney diseases (CKD) require them, owing to the low absorption of iron and decline in appetite due to kidney failure. In addition, patients who suffer from ESRD and undergo dialysis are the major consumers of I.V. iron products. This segment is expected to further benefit the global I.V. iron market in the coming years, chiefly due to an expected increase in the number of CKD and dialysis patients worldwide.
•
Outside dialysis, I.V. iron treatments find applications in many other therapeutic areas, especially for elderly population, as they are more prone to chronic diseases, which can further lead to iron deficiency. Also the increasing healthcare expenditure is likely to boost the growth of the market as I.V. iron therapies are comparatively costly.
•
All the factors mentioned above are certain to boost the performance of the global I.V. iron drug market, which is forecasted to reach US$... million by the end of 2019 from US$... million in 2014. The global market for I.V. iron drug is expected to grow at a CAGR of …% during the five year period from 2014 to 2019.
Contact Us: Details View Report These are abridged and sanitized sample pages from the comprehensive report on the “ Global IV Iron Drugs Market ”. To know more about this report or for any customized research requirement, please contact the following:
Koncept Analytics
Vikas Gupta BD Manager
CS-36, Second Floor, Ansal Plaza Vaishali, Ghaziabad, U.P. – 201010 T. +91-120-4130959 C: +91-9811715635 vikas@konceptanalytics.com
www.konceptanalytics.com